Clinical Trial

Efficacy of a Probiotic Formulation in Adults With Lactose Intolerance and Methanogenic Intestinal Overgrowth

Study acronym: LAC L-134/33
Completed
View on ClinicalTrials.gov →
Summary
Introduction: Lactose intolerance (LI) is characterized by specific gastrointestinal symptoms following the consumption of dairy products and lactose-containing foods, symptoms that may also be experienced by individuals with intestinal methanogenic overgrowth (IMO). However, such clinical manifestations may be modulated by the use of probiotics; the aim of this study was to analyze the preliminary efficacy of a probiotic formulation on gastrointestinal symptoms in adults with LI and IMO. Materials and Methods: A randomized, double-blind, placebo-controlled pilot study was conducted with 22 adults who tested positive on a hydrogen breath test (HBT); they were assigned to intervention or placebo groups based on their diagnosis. Accordingly, they completed a Questionnaire on symptoms of Lactose Intolerance (QSLT) and underwent successive nutritional assessments.
Trial Details
NCT Number NCT07652827
Lead Sponsor Universidad de Concepcion
Conditions Lactose Intolerance
Enrollment 22 participants
Start Date 2024-08-12
Primary Completion 2025-01-06 (estimated)
Study Completion 2025-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-17